1. Behcet's-like syndrome following pembrolizumab: An immune-related adverse event associated with programmed death receptor-1 inhibitor therapy. (June 2020) Authors: Thomas, Steffi; Bae, Chay; Joy-Ann, Tabanor; Traverse, William Journal: Journal of oncology pharmacy practice Issue: Volume 26:Number 4(2020) Page Start: 995 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗